Stem Cell Therapy Market 2020 : Top Countries Data, Industry Size, Growth Factors, Defination, Global Analysis, Opportunities And Forecast To 2026 -…

Global Stem Cell Therapy Market 2020 Research Report provides key analysis on the market status of the Stem Cell Therapy manufacturers with best facts and figures, meaning, definition, SWOT analysis, expert opinions and the latest developments across the globe. The Report also calculate the market size, Stem Cell Therapy Sales, Price, Revenue, Gross Margin and Market Share, cost structure and growth rate. The report considers the revenue generated from the sales of This Report and technologies by various application segments.

Final Report will add the analysis of the impact of COVID-19 on this Stem Cell Therapy industry.

The objective of the study is to define market sizes of different segments and countries in previous years and to forecast the values to the next Five years. The report is designed to incorporate both qualify qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers and restraining factors which will define the future growth of the Stem Cell Therapy market.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/15067862

The research covers the current Stem Cell Therapy market size of the market and its growth rates based on 6-year records with company outline of Key players/manufacturers:

Short Description about Stem Cell Therapy Market:

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Scope of the Stem Cell Therapy Market Report :

In 2019, The Global Stem Cell Therapy market size was USD 403.6 million and it is expected to reach USD 1439.9 million by the end of 2026, with a CAGR of 19.7% during 2021-2026.

This report focuses on the Stem Cell Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Copy of the Stem Cell Therapy Market Report 2020

Report further studies the market development status and future Stem Cell Therapy Market trend across the world. Also, it splits Stem Cell Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell Therapy in these regions, from 2015 to 2026, covering

This Stem Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/15067862

Major Points from Table of Contents:

Global Stem Cell Therapy Market Research Report 2020-2026, by Manufacturers, Regions, Types and Applications

1 Study Coverage1.1 Stem Cell Therapy Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.4.1 Global Stem Cell Therapy Market Size Growth Rate by Type1.5 Market by Application1.5.1 Global Stem Cell Therapy Market Size Growth Rate by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Stem Cell Therapy Production2.1.1 Global Stem Cell Therapy Revenue 2015-20262.1.2 Global Stem Cell Therapy Production 2015-20262.1.3 Global Stem Cell Therapy Capacity 2015-20262.1.4 Global Stem Cell Therapy Marketing Pricing and Trends2.2 Stem Cell Therapy Growth Rate (CAGR) 2020-20262.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Key Stem Cell Therapy Manufacturers2.4 Market Drivers, Trends and Issues2.5 Macroscopic Indicator2.5.1 GDP for Major Regions2.5.2 Price of Raw Materials in Dollars: Evolution

3 Market Size by Manufacturers3.1 Stem Cell Therapy Production by Manufacturers3.1.1 Stem Cell Therapy Production by Manufacturers3.1.2 Stem Cell Therapy Production Market Share by Manufacturers3.2 Stem Cell Therapy Revenue by Manufacturers3.2.1 Stem Cell Therapy Revenue by Manufacturers (2015-2020)3.2.2 Stem Cell Therapy Revenue Share by Manufacturers (2015-2020)3.3 Stem Cell Therapy Price by Manufacturers3.4 Mergers and Acquisitions, Expansion Plans

4 Stem Cell Therapy Production by Regions4.1 Global Stem Cell Therapy Production by Regions4.1.1 Global Stem Cell Therapy Production Market Share by Regions4.1.2 Global Stem Cell Therapy Revenue Market Share by Regions4.2 United States4.2.1 United States Stem Cell Therapy Production4.2.2 United States Stem Cell Therapy Revenue4.2.3 Key Players in United States4.2.4 United States Stem Cell Therapy Import and Export4.3 Europe4.3.1 Europe Stem Cell Therapy Production4.3.2 Europe Stem Cell Therapy Revenue4.3.3 Key Players in Europe4.3.4 Europe Stem Cell Therapy Import and Export4.4 China4.4.1 China Stem Cell Therapy Production4.4.2 China Stem Cell Therapy Revenue4.4.3 Key Players in China4.4.4 China Stem Cell Therapy Import and Export4.5 Japan4.5.1 Japan Stem Cell Therapy Production4.5.2 Japan Stem Cell Therapy Revenue4.5.3 Key Players in Japan4.5.4 Japan Stem Cell Therapy Import and Export4.6 Other Regions4.6.1 South Korea4.6.2 India4.6.3 Southeast Asia

5 Stem Cell Therapy Consumption by Regions5.1 Global Stem Cell Therapy Consumption by Regions5.1.1 Global Stem Cell Therapy Consumption by Regions5.1.2 Global Stem Cell Therapy Consumption Market Share by Regions5.2 North America5.2.1 North America Stem Cell Therapy Consumption by Application5.2.2 North America Stem Cell Therapy Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Stem Cell Therapy Consumption by Application5.3.2 Europe Stem Cell Therapy Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Stem Cell Therapy Consumption by Application5.4.2 Asia Pacific Stem Cell Therapy Consumption by Countries5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines5.4.12 Vietnam5.5 Central and South America5.5.1 Central and South America Stem Cell Therapy Consumption by Application5.5.2 Central and South America Stem Cell Therapy Consumption by Countries5.5.3 Brazil5.6 Middle East and Africa5.6.1 Middle East and Africa Stem Cell Therapy Consumption by Application5.6.2 Middle East and Africa Stem Cell Therapy Consumption by Countries5.6.3 Turkey5.6.4 GCC Countries5.6.5 Egypt5.6.6 South Africa

6 Market Size by Type6.1 Global Stem Cell Therapy Breakdown Dada by Type6.2 Global Stem Cell Therapy Revenue by Type6.3 Stem Cell Therapy Price by Type

7 Market Size by Application7.1 Overview7.2 Global Stem Cell Therapy Breakdown Dada by Application7.2.1 Global Stem Cell Therapy Consumption by Application7.2.2 Global Stem Cell Therapy Consumption Market Share by Application (2015-2020)

Continued.

Purchase this report (Price 3900 USD for a single-user license) https://www.360researchreports.com/purchase/15067862

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:Name: Mr. Ajay MoreEmail: [emailprotected]Organization: 360 Research ReportsPhone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Weatherstrip Seal Market 2020 : Top Countries Data, Growth Factors, Defination, Business Opportunity, Trend, Segmentation and Forecast to 2026

Organic Soy Lecithin Market Size 2020 : Top Countries Data, Defination, Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026

Bottle Sealing Wax Market Size 2020 : Top Countries Data, Defination, Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Stem Cell Therapy Market 2020 : Top Countries Data, Industry Size, Growth Factors, Defination, Global Analysis, Opportunities And Forecast To 2026

See the original post here:
Stem Cell Therapy Market 2020 : Top Countries Data, Industry Size, Growth Factors, Defination, Global Analysis, Opportunities And Forecast To 2026 -...

ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple…

FARMINGTON, Conn., March 20, 2020 /PRNewswire/ --ImStem Biotechnology, Inc. (Farmington CT), a biopharmaceutical company pioneering the development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), through a proprietary method using a trophoblast intermediate stage (hence also known as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS). IMS001 is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. We believe this is the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA. The company plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.

"As an inventor of our proprietary technology, we look forward to building a company whose foundation lies in our science based upon years of pioneering research," said Dr. Xiaofang Wang, Chief Technology Officer of ImStem Biotechnology.

About IMS001

IMS001 is an investigational, allogeneic, hES-MSC product derived from human embryonic stem cell line. IMS001 has demonstrated preclinical immunomodulatory and blood-brain-barrier (BBB) repair activities, which may lead to potential therapeutic benefits in a wide array of neurological, autoimmune, and rare orphan diseases with high unmet medical needs. These mechanistic properties may lead to therapeutic benefits in diseases such as MS, potentially reducing relapses, disability progression, and inducing disease arrest.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The company's mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem biotechnology Inc. is a privately held company headquartered in Farmington, CT. For more information, visit http://www.imstem.com.

Media Contact:Investor Relations235411@email4pr.com860-281-7836

View original content:http://www.prnewswire.com/news-releases/imstem-biotechnology-announces-fda-has-lifted-the-clinical-hold-on-the-investigational-new-drug-application-for-ims001-for-the-treatment-of-multiple-sclerosis-301027733.html

SOURCE ImStem Biotechnology, Inc.

Original post:
ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple...

An unusual chance to see stress at work – Big Think

It's not your imagination, it turns out. Stress can turn a person's hair gray. It's said that if you look at before and after pictures of any eight-year U.S. president the impact of the office on hair color is clear, though in fairness, it may be that candidates dye their hair and then at some point stop doing so. Nonetheless, scientists from Harvard have not only verified the conventional wisdom on our graying noggins, but have also figured out why stress is so brutal to our follicular pigmentation.

The new research from Harvard scientists is published in the journal Nature.

Image source: Ververidis Vasilis/Evan El-Amin/Vacclav/Shutterstock/Big Think

Senior author of the study Ya-Chieh Hsu, professor of Stem Cell and Regenerative Biology at Harvard, explains what prompted her research:

"Everyone has an anecdote to share about how stress affects their body, particularly in their skin and hair the only tissues we can see from the outside. We wanted to understand if this connection is true, and if so, how stress leads to changes in diverse tissues. Hair pigmentation is such an accessible and tractable system to start with and besides, we were genuinely curious to see if stress indeed leads to hair graying."

It turns out that stress activates nerves associated with our basic fight-or-flight system, and these nerves permanently damage pigment-regenerating melanocyte stem cells in hair follicles, causing them to cease production of melanin that normal provides color to hair follicles.

Hsu's team studied the issue using mice, and was somewhat stunned at their findings. "When we started to study this, I expected that stress was bad for the body but the detrimental impact of stress that we discovered was beyond what I imagined," recalls Hsu.

The scientists stressed the mice using a combination of three methods:

Image source: Helga Lei/Shutterstock

Hsu and her colleagues first suspected an immune system reaction was at the root of graying hairs only to discover that mice without immune systems still turned gray in response to stressors. The next suspect was cortisol produced by the adrenal glands however, this proved not to be so. "Stress always elevates levels of the hormone cortisol in the body," says Jsu, "so we thought that cortisol might play a role. But surprisingly, when we removed the adrenal gland from the mice so that they couldn't produce cortisol-like hormones, their hair still turned gray under stress."

Image source: Judy Blomquist/Harvard University

Finally, the researchers investigate the possibility that the system responding to stressors was the mice's sympathetic nervous systems, the part of the nervous system that kicks into action with the fight-or-flight impulse. The sympathetic nervous system is a vast network of nerves that connects, among other places, to hair follicles in the skin. In response to stress, the system sends a rush of the chemical norepinephrine to the follicles' melanocyte stem cell, causing them to quickly burn through and deplete their stores of pigment.

Say Hsu, "After just a few days, all of the pigment-regenerating stem cells were lost. Once they're gone, you can't regenerate pigments anymore. The damage is permanent." Great for survival, not so good for hair color.

Sympathetic system nerves are magenta above. Melanocyte stem cells are yellow.

Image source: Hsu Laboratory, Harvard University

"Acute stress," says lead author of the study Bing Zhang, "particularly the fight-or-flight response, has been traditionally viewed to be beneficial for an animal's survival. But in this case, acute stress causes permanent depletion of stem cells."

The research, done in collaboration with other Harvard researchers, presents a new appreciation of the effect the sympathetic system can have on the body's cells during stress.

One of these collaborators, Harvard immunologist Isaac Chu, notes, "We know that peripheral neurons powerfully regulate organ function, blood vessels, and immunity, but less is known about how they regulate stem cells. With this study, we now know that neurons can control stem cells and their function, and can explain how they interact at the cellular and molecular levels to link stress with hair graying."

Given this finding regarding the direct impact of stress on follicular stem cells, the question of what it else it may affect becomes an obvious one. As Hsu sums it up, "By understanding precisely how stress affects stem cells that regenerate pigment, we've laid the groundwork for understanding how stress affects other tissues and organs in the body."

This importance of the study therefore goes way beyond graying heads. "Understanding how our tissues change under stress is the first critical step," says Hsu, "toward eventual treatment that can halt or revert the detrimental impact of stress. We still have a lot to learn in this area."

Related Articles Around the Web

See the original post:
An unusual chance to see stress at work - Big Think

AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for…

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the U.S. Food and Drug Administration (FDA) that it has lifted the hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS). IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX.

"Since pluripotent stem cells are capable of differentiating into all human cell types potentially genetically modified in any manner, they open the door to a wide array of new therapies," stated Dr. Michael D. West, PhD, founder and CEO of AgeX. "This collaboration with ImStem is consistent with our aim to make our clinical-grade pluripotent stem cell banks widely available for diverse therapeutic applications."

IMS001 is a formulation of cells derived from AgeX pluripotent stem cells induced to differentiate into mesenchymal cells (hES-MSC) and through a proprietary method using a trophoblast intermediate stage (hence also known as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases. IMS001 is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. ImStem believes this is the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA. ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.

"The clinical-grade pluripotent stem cell lines from AgeX were the first published GMP-compatible lines ever created," said Xiaofang Wang, MD, PhD, Founder and Chief Technology Officer of ImStem. "As such, they have been widely distributed in the scientific community and demonstrated to meet the needs of industry for relatively rapid product development."

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About IMS001

IMS001 is an investigational, allogeneic, hES-MSC that has undergone IND-enabling, preclinical biodistribution, engraftment, tumorigenicity, toxicology, immunogenicity, and pharmacology studies. IMS001 has demonstrated preclinical immunomodulatory activities, which may lead to potential therapeutic benefits in a wide array of neurological, autoimmune, and rare orphan diseases with high unmet medical needs.

Previously published in-vitro data, in collaboration with scientists at the University of Connecticut (UConn) Health, have demonstrated potential advantages of hESC-MSCs in terms of their immunomodulatory effects, as well as the potential to stabilize the blood-brain-barrier (BBB). These mechanistic properties may lead to therapeutic benefits in diseases such as MS, potentially reducing relapses, disability progression, and inducing disease arrest.

Story continues

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The companys mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology, Inc. is a privately held company headquartered in Farmington, CT. For more information, visit http://www.imstem.com.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005140/en/

Contacts

Media Contact for AgeX:

Bill Douglass Gotham Communications, LLCbill@gothamcomm.com (646) 504-0890

See the rest here:
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for...

Trail & Tunnel Notes From the Friends of the Old Croton Aqueduc – River Journal Staff

The Lazy Walkers on the Keepers House porch.Credit: Friends of the Old Croton Aqueduct

Visitors to the Keepers House in Dobbs Ferry often provide stories as intriguing as the house itself, offering a reward to those of us who work as docents there. Here are a sample:

Echoes of Downton Abbey

At four oclock one winter afternoon, I was about to close up when a lone visitor arrived. When I learned that he had come all the way from Astoria, Queens, of course I said, Ill stay open for you. And when I heard his German accent, I couldnt resist a chat to practice my own German. I asked, Was ist ihr Beruf? (What is your profession?) He answered, Ich bin Haushalt Meister. I didnt understand, so he helped me out: Butler to you. I asked, You mean like Carson in Downton Abbey? Yes.

His name is Niklaus. He is, now, as far as I know, the only butler on our membership list.

The Bearded Santa Claus

In early December, a walker arrived who had a long straggly beard, carried a walking stick, backpack, and was wearing sturdy boots and a heavy, well-worn jacket. He deposited himself on a chair, saying he needed a rest. Then to my astonishment he pulled out a wad of hundred dollar bills, saying, I need some maps. He needed $200 worth of maps, To give as Christmas presents.

You must be Santa Claus! I said. He answered, I cant be because Im Jewish, then handed me another hundred dollar bill as a donation.

I learned that he is a mathematician who, as he put it, haunts the halls of MIT.

How Many Walkers Come from Iceland?

So far only two. Recently, an attractive young couple arrived at the House and were fascinated by our story. Of course, I had to get their story. They were doing a short stem-cell research assignment at Sloan Kettering. But how did they find the Keepers House?

The answer was: If you are Scandinavian, or European of any kind, you love to walk. And so you Google Interesting walks. And the Aqueduct pops up. Their explanation made sense; no wonder we get so many European tourists.

The Best-Dressed Bikers in the World

One afternoon, a couple walked in looking as if theyd stepped out of a Gentlemans Quarterly for international bikers, with the correct gloves, shoes and gaiters, and matching vests and helmets.

Recently retired from the medical world in Bremen, Germany, they had flown, with their fancy bikes, to Toronto to bike the Lake Shore and then the Erie Canal. Someone on the Erie Canal route recommended visiting the Keepers House. Thats a hop, skip, and a jump!

While his wife was in the bathroom, the man said to another visitor (from Quebec, as it happens), Dont tell my wife, but Im planning a tour of the Gasp Peninsula in Quebec next year. Well see.

The Trespassers of Decades Ago

Local teenagers had possessed the Keepers House long before we did. We called them our happy trespassers. When we started restoring the broken-down house, we were thrilled to discover, written on the wall of an upstairs room, The Explorers Club. There followed a list of rather childishly written names of neighborhood kids who had hung out in the abandoned house, perhaps climbing in through a cellar window. We took a photograph of the names on the wall before we painted over it. It was as much their house then as it is ours now. I discovered, with a bit of sleuthing, that one of the explorers is still in the neighborhood. I asked if we could take a photo of her and her cousins fellow explorers. She declined, not wanting to be labeled a trespasser. But she understood our pleasure at finding the list before we painted the walls.

The Lazy Walkers

One quiet afternoon, a diverse group of 30 walkers, of various ages, straggled into the House. They obviously needed a rest, having walked almost all the way to Dobbs Ferry from Manhattan. I asked if they were a special group, and they said, We call ourselves The Lazy Walkers. And to think they walked all the way from Manhattan. They said the name gives them permission to dawdle. (But they left the house at a gallop.)

..

I encourage readers to pay a visit to the Keepers House and leave a story behind. And if youd like to be docent, call Mavis at 914-693-0529.

More here:
Trail & Tunnel Notes From the Friends of the Old Croton Aqueduc - River Journal Staff

Stem Cell Therapy Market 2020 Demand with Global Forecast by Top Leading Players: Osiris Therapeutics, Medipost Co., Anterogen Co., Pharmicell Co.,…

New Jersey, United States: A qualitative research study accomplished by Verified Market Research titled 2020-2026 Global and Regional Stem Cell Therapy Market: Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report is the most up to date report which comprises the latest trends that influence the market competition in the forecast period from 2020 to 2026. The report presents different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. Primarily, the report introduces market demands and the present position of the Stem Cell Therapy market.The report completes the value chain and downstream and upstream essentials.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. The growth potential, market share, size, and prospects of each segment and sub-segment are portrayed in the report. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Stem Cell Therapy Market.

A number of leading manufacturers mention in the Stem Cell Therapy Market research report are focusing on expanding operations in regions, as they exhibit potential business opportunities. The Stem Cell Therapy Market report classifies the market dynamics and trends in the global and regional market considering several aspects including technology, supplies, capacity, production, profit, and price.

Stem Cell Therapy Market: Research Methodology

1. Primary Research:

2. Secondary Research:

During our Secondary research, we collect information from different sources such as databases, regulatory bodies, gold and silver-standard websites, articles by recognized authors, certified publications, white papers, investor presentations and press releases of companies, and annual reports.

Data collection module is used for data collection and analysis of the base year. The market data is analyzed and estimated using statistical models and systematic market. The main research methodology used for the preparation of reports, including data mining, primary (industry experts) validation and top-down analysis, market overview and guidance, the company market share analysis, measurement standards, and analysis of the stock sellers.

Vendor Competitive Analysis:

The report focuses on the strategies considered by the market participants to gain a major share in the Stem Cell Therapy market. Through this, the competitors will get an overview of the competitive landscape so they can make business decisions. Leading players working in the global market are analyzed with their company information, product profile, product specification, picture, capacity, production, price, cost, global investment plans, and supply-demand scenarios.

Stem Cell Therapy Market Regional Coverage

The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Ask For Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=PN24&utm_medium=002

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=PN24&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis, Stem Cell Therapy Market Business Opportunities and Stem Cell Therapy Market Outlook

Continued here:
Stem Cell Therapy Market 2020 Demand with Global Forecast by Top Leading Players: Osiris Therapeutics, Medipost Co., Anterogen Co., Pharmicell Co.,...

Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights – BioSpace

MENLO PARK, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Forty Seven Inc., (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.

In 2019, Forty Seven transformed into a multi-asset, late-stage development company with clear paths to registration in two distinct, underserved patient populations. In parallel, we entered into several new partnerships designed to accelerate the development of magrolimab and FSI-174, and allow us to evaluate both compounds more rapidly across a range of indications and combination paradigms, said Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of Forty Seven. Following the recently announced acquisition by Gilead, and with the benefit of their resources and capabilities, we are even better positioned to build on this momentum and deliver on our foundational vision of developing novel immunotherapies that help patients defeat their cancers.

Dr. McCamish continued, Like so many others, we are closely monitoring COVID-19, and have recently instituted a number of proactive measures to mitigate the spread of the virus and protect the safety, health and well-being of the patients, families and healthcare professionals involved in our clinical development programs, as well as our employees. While we are working diligently to limit the impact of COVID-19 on our ongoing clinical trials, we, together with our contract research organization, decided to delay the initiation of our Phase 1 trial of FSI-174 in healthy volunteers in order to support physicians and hospitals in devoting their resources to treating COVID-19 patients, and avoid exposing healthy volunteers to unnecessary risk. We will continue to evaluate the pandemic and expect to re-visit the timing of potential trial initiation in the second quarter.

Fourth Quarter and Recent Business Highlights:

Magrolimab Clinical Programs:Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Diffuse Large B Cell Lymphoma (DLBCL)

Solid Tumors

FSI-174:

FSI-189:

Corporate:

Fourth Quarter and Full Year 2019 Financial Results:

About Forty Seven, Inc.Forty Seven, Inc.is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed fromStanford University. Forty Sevens lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a dont eat me signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia and non-Hodgkins lymphoma. In March 2020, Forty Seven entered into a definitive agreement to be acquired by Gilead Sciences, Inc., which is expected to close during the second quarter of 2020.

Additional Information and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Forty Seven, nor is it a substitute for any tender offer materials that Gilead, its acquisition company or Forty Seven has or will file with the SEC. A solicitation and an offer to buy shares of Forty Seven will be made only pursuant to an offer to purchase and related materials that Gilead has filed with the SEC. At the time the tender offer was commenced, Gilead filed a Tender Offer Statement on Schedule TO with the SEC, and Forty Seven filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. FORTY SEVENS STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, has been sent to all stockholders of Forty Seven at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement are available for free at the SEC's web site at http://www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Forty Seven. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Copies of the documents filed with the SEC by Forty Seven will be available free of charge under the Investors section of Forty Sevens internet website at ir.fortyseveninc.com.

Forward-Looking Statements:

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expect, potential, plans, will, believe, and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing and outcome of results from the Phase 1b trial evaluating magrolimab in combination with azacitidine for the treatment of MDS and AML, the potentially-registration enabling clinical development program for magrolimab in higher-risk MDS, the single-arm, registration enabling trial evaluating the combination of magrolimab and rituximab in heavily pre-treated relapsed or refractory DLBCL patients, and other ongoing trials of 5F9 for the treatment of ovarian and colorectal cancer; the timing of and quality of results from investigational new drug-application enabling studies for FSI-189 and FSI-174 and their respective potential for approval by the FDA; the timing and success of research and development plans for Rockets and Forty Sevens respective platforms, product candidates and collaboration; the timing and success of research and development plans for bluebirds and Forty Sevens respective platforms, product candidates and collaboration; the business combination with Gilead and related matter; post-closing operations and the outlook for the companies respective businesses, including, without limitation, the ability of Gilead to advance Forty Sevens product pipeline, including magrolimab, FSI-174 and FSI-189; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; difficulties or unanticipated expenses in connection with integrating the companies; Forty Sevens ability to fund its clinical programs and the sufficiency of its cash and short-term investments, and Forty Sevens financial outlook; and any assumptions underlying any of the foregoing.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by such forward-looking statements include: the potential product candidates that Forty Seven develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or successfully commercialized; uncertainties as to the timing of the business combination with Gilead; the possibility that various closing conditions for the business combination may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of the business combination on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or political conditions outside of the companies control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies periodic reports filed with the U.S. Securities and Exchange Commission (the SEC), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Forty Seven and the Schedule TO and related tender offer documents filed by Gilead and Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead and Forty Seven, and Gilead and Forty Seven assume no obligation and disclaim any intent to update any such forward-looking statements.

For more information please visit http://www.fortyseveninc.com or contactinfo@fortyseveninc.com.

For journalist enquiries please contact Sarah Plumridge atfortyseven@hdmz.comor phone (312) 506-5218.

For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. athannah.deresiewicz@sternir.comor phone (212) 362-1200.

Forty Seven Inc.Statements of Operations and Comprehensive Loss Data(In thousands, except share and per share data)

Forty Seven Inc.Selected Balance Sheet Data(in thousands)

Read the rest here:
Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights - BioSpace

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : Drivers, Restraints, Opportunities, and Threats (2019-2025) – Packaging News 24

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/18928?source=atm

For competitor segment, the report includes global key players of Platelet Rich Plasma and Stem Cell Alopecia Treatment as well as some small players.

Companies Mentioned in the Report

The report also profiles major players operating in the global platelet rich plasma & stem cell alopecia treatment market based on various attributes, such as company overview, financial overview, pipeline portfolio, product portfolio, business strategies, and recent developments. The players covered in the report include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented as below:

Request Sample Report @https://www.mrrse.com/sample/18928?source=atm

Important Key questions answered in Platelet Rich Plasma and Stem Cell Alopecia Treatment market report:

What will the market growth rate, Overview, and Analysis by Type of Platelet Rich Plasma and Stem Cell Alopecia Treatment in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Platelet Rich Plasma and Stem Cell Alopecia Treatment market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Platelet Rich Plasma and Stem Cell Alopecia Treatment market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

Buy This Report @ https://www.mrrse.com/checkout/18928?source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Platelet Rich Plasma and Stem Cell Alopecia Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Platelet Rich Plasma and Stem Cell Alopecia Treatment , with price, sales, revenue and global market share of Platelet Rich Plasma and Stem Cell Alopecia Treatment in 2019 and 2015.

Chapter 3, the Platelet Rich Plasma and Stem Cell Alopecia Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Platelet Rich Plasma and Stem Cell Alopecia Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Platelet Rich Plasma and Stem Cell Alopecia Treatment market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Platelet Rich Plasma and Stem Cell Alopecia Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the original:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : Drivers, Restraints, Opportunities, and Threats (2019-2025) - Packaging News 24

Coronavirus treatment research is delayed by Trumps ban on the use of fetal tissue – Vox.com

President Donald Trump has repeatedly said that the US is working to develop a vaccine for Covid-19, the disease caused by the novel coronavirus, as quickly as possible. But one of his own administrations policies appears to be standing in the way of at least one scientist.

According to a report by the Washington Posts Amy Goldstein, Kim Hasenkrug, an immunologist at the National Institutes of Healths Rocky Mountain Laboratories in Montana, wants to test potential treatments for Covid-19 in mice with humanized lungs. But as the Post first reported, the work is being held up by officials at the Department of Health and Human Services due to a 2019 ban on NIH scientists using donated fetal tissue from abortions in their research.

While fetal tissue isnt typically used to develop actual therapies or treatments, it has one particularly key use for researchers: the ability to create mice with human tissue suitable for medical testing. Mice, generally, have similar immune systems to humans, making them particularly useful for early medical testing.

Humanized mice have been key to developing several important medical treatments for diseases like the Zika virus or HIV/AIDS, which was Hasenkrugs previous research focus. The calculation is simple. You cant test certain treatments without humanized mice, and you cant get humanized mice without fetal tissue.

There are, of course, many avenues of research using other kinds of tissue, but fetal cells can rapidly divide, grow, and adapt to new environments in ways that make them the gold standard for some disease research. And in other research areas, we dont yet know if there is anything that could substitute, R. Alta Charo, professor of law and bioethics at the University of Wisconsin at Madison, wrote in the New England Journal of Medicine in 2015.

And as the Posts Goldstein noted, scientists have already shown that humanized mice could make good test subjects for coronavirus treatments specifically:

Just months ago, before the new coronavirus began to infect people around the world, other U.S. scientists made two highly relevant discoveries. They found that specialized mice could be transplanted with human fetal tissue that develops into lungs the part of the body the new coronavirus invades. These humanized mice, they also found, could then be infected with coronaviruses to which ordinary mice are not susceptible closely related to the one that causes the new disease, Covid-19.

Outside researchers have offered the mice to Hasenkrug for coronavirus research. But so far, Hasenkrug and other government researchers havent been allowed to obtain the mice they need to perform testing, the Post reported, thanks to a June 2019 HHS directive banning fetal tissue research for those employed by the government.

Caitlin Oakley, a HHS spokesperson, told the Post that no decision has been made about Hasenkrugs request. A separate HHS spokesperson confirmed that in a statement to Vox.

The spokesperson also pointed to an HHS statement from last June detailing the administrations policy on fetal tissue research. Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trumps administration, reads the statement.

Hasenkrug, and the potentially millions of Americans who may benefit from his research, now find themselves caught in a deeply divisive political issue thats been years in the making.

The US government had funded fetal tissue research efforts since the 1950s and for nearly as long, anti-abortion activists have opposed the practice.

In the Trump era, they finally found an administration ready to listen.

In 2018, the US government spent $115 million on about 173 research projects utilizing fetal tissue, a third of which were devoted to developing therapies for HIV/AIDS.

Research using fetal tissue has led to the development of vaccines such as those for polio, rubella, and measles, the International Society for Stem Cell Research (ISSCR) said in a statement last September. Fetal tissue is still helping advance science, with research underway using cells from fetal tissue to evaluate conditions including Parkinsons disease, ALS, and spinal cord injury. Fetal tissue is also necessary for the development of potential treatments for Zika virus and HIV/AIDS.

But anti-abortion activists argue it incentivizes abortion providers to perform more abortions in order to procure more tissue they could sell to third-party companies, which then provide the tissue directly to researchers. Fetal tissue procurement has been heavily regulated since enactment of the NIH Revitalization Act of 1993, which states that profits cannot be made in the transfer or acceptance of fetal tissue for research purposes.

That hasnt stopped anti-abortion activists from continuing to call into question the ethics of abortion providers or procurement companies. In 2000, the anti-abortion rights group Life Dynamics seemingly began the practice of releasing false or deceptively edited videos targeting the fetal tissue sales process. The main source in their videos was found to be not credible.

The George W. Bush administration did not take action against fetal tissue research, instead enacting restrictions on stem cell research derived from embryos in an August 2001 executive order. Those restrictions were later rolled back by an executive order from President Barack Obama in 2009.

More recently, the anti-abortion rights group Center for Medical Progress, run by activist David Daleiden, infamously released heavily edited videos appearing to show a Planned Parenthood employee negotiating prices for fetal tissue, and CMP accused the abortion care provider of illegally profiting from sales.

The videos caught the attention of Republican lawmakers. Investigations by the House Energy and Commerce, House Judiciary, and Oversight and Government Reform committees found no wrongdoing. Further investigations into Planned Parenthood and fetal tissue transfer proceeded with the creation of the Select Investigative Panel on Infant Lives in October 2015, chaired by Rep. Marsha Blackburn (R-TN), leading to $1.59 million in spending and a 471-page final report making numerable anti-abortion recommendations.

Among those requests was a call for the government to ban fetal tissue research by government scientists, which Barack Obamas administration, which favored the practice, ultimately ignored.

Democrats on the committee released their own report, disputing the conclusions of their Republican colleagues. At the end of their crusade, the conclusion was undeniable: There was no wrongdoing on behalf of fetal tissue researchers, including Advanced Bioscience Resources, or anyone else in the fetal tissue research space, said Rep. Jan Schakowksy (D-IL), who served as the ranking Democrat on the select committee, in a statement to Rewire.News in October 2018.

Anti-abortion activists saw an opportunity to advance their agenda on fetal tissue research when President Donald Trump won election in 2016, but it took a conservative media freakout in 2018 to enact new restrictions.

Over the summer of 2018, conservative media focused on several transactions by Advanced Bioscience Resources, a company that procured fetal tissue from abortion providers and shipped it to researchers for use. ABR was also one of the subjects of the 2015 select committee investigation.

HHS decided to cancel the governments contract with ABR in late September 2018 and began a review of the agencys rules and processes for procuring fetal tissue for research. That review concluded last summer, with HHS announcing in June that it would ban any fetal tissue studies by in-house NIH scientists, like Hasenkrug. It also introduced strict paperwork requirements for any outside scientists conducting research funded by the government.

The decision came as welcome news to anti-abortion activists. The language is trying to hold an ethical standard for the research proposals and the research that might be done. The policy is not just about science. Its also about ethics, David Prentice, vice president and research director at the anti-abortion Charlotte Lozier Institute, told Science magazine last July.

For his part, Hasenkrug has reportedly asked the Trump administration several times for permission to begin working with UNCs humanized mice for a coronavirus cure, but is still waiting on permission. Per the Post:

On Feb. 19, two people said, Hasenkrug wrote to a senior NIH official, asking for permission to use those mice and run experiments related to covid-19. He eventually was told that his request had been passed on to senior HHS officials.

Since then, he has written repeatedly to NIH, laying out in greater detail the experiments he wants to undertake and why several alternatives to the fetal tissue-implanted mice would not be as useful. In one appeal to NIH, Hasenkrug wrote that the mice he was offered are more than a year old and have a relatively short time remaining to live, so they should be used quickly, according to Kerry Lavender, a Canadian researcher familiar with the correspondence.

Hasenkrugs request has reportedly been forwarded to the White House Domestic Policy Council, which is chaired by Trump himself, but the government has not made a decision on the research as of yet.

See the rest here:
Coronavirus treatment research is delayed by Trumps ban on the use of fetal tissue - Vox.com

Recombinant Cell Culture Supplements Receive a Boost from Stem Cell Research Ventures; Demand for Novel Vaccines to Act as a Growth Lever, Says PMR -…

New York, United States, March 20, 2020 (GLOBE NEWSWIRE) -- The global recombinant cell culture supplements market, valued at US$ 320 Mn by the end of 2018, will grow at a steady rate from 2029-2029. The market players are investing in research and development activities to create new vaccines. They are targeting developing nations such as India and China for the same to benefit from their favorable government policies regarding foreign investments. Manufacturers are enhancing their presence across different distribution networks to market their products.

Recombinant Cell Culture Supplements Market: Key Takeaways

Request for sample Report: https://www.persistencemarketresearch.com/samples/31310

Recombinant Cell Culture Supplements Market: Key Growth Drivers

Recombinant Cell Culture Supplements Market: Key Restraints

The complete recombinant cell culture supplements market report with detailed market segmentation, 200 illustrative figures, and 63 data tables spread across 306 pages onhttps://www.persistencemarketresearch.com/methodology/31310

Recombinant Cell Culture Supplements Market: Competition LandscapeThe competition landscape is highly intense where every player is expanding its product portfolio to stay at the forefront in the market. established players are acquiring regional players to strengthen their regional footprint. For instance, Thermo Fisher Scientific acquired the bio-processing business of Becton Dickinson to expand its product portfolio.

Get Persistence Market Research's Detailed Coverage OnCell Culture Media Market: Get intensive information on the global cell culture media market with vital updates on market growth drivers, changing market dynamics, existing market challenges, government policies and laws, segmental market forecast and key market strategies prominent players.

Human Platelet Lysate Market: PMR's study on the global human platelet lysate market provides an exhaustive analysis of the market set for steady during 2019-2029. The study also elaborates on a detailed evaluation of key forces influencing growth in the market, major revenue strategies and key market players with their winning market strategies.

Autogenous Vaccines Market: Get vital information on the global autogenous vaccines market with segment-based analysis, major market statistics, and key growth factors, prominent market players and key marketing strategies adopted by them for a period under projection.

Gain access to Market Ngage, an AI-powered, real-time business intelligence platform that goes beyond the conventional research solutions to solve the complex strategy challenges that organizations face today.

About the ReportPersistence Market Research's market research study on the recombinant cell culture supplements market contains a global analysis of the market through20142018and provides growth assessment for20192029. The study offers insightful details of the hydrogen market through four major segments delivery mode, end-use, production method, and region.

About Persistence Market Research

Persistence Market Research (PMR) is an innovative and specialized supplier ofmarket intelligence reportsandconsulting services. Prompt delivery, in-depth research, and high quality are the sacrosanct principles of PMR. The company's research capabilities cover 5 continents, 1500+ reports, and 8 next-gen vertical expertise that have been catering to research demands of 5000+ clients.

Contact:

Rajendra Singh

Persistence Market Research

U.S. Sales Office:

305 Broadway, 7th Floor

New York City, NY 10007

+1-646-568-7751

United States

USA - Canada Toll-Free: 800-961-0353

For Sales Enquiries: sales@persistencemarketresearch.com

For Media Enquiries: media@persistencemarketresearch.com

Research Report: https://www.persistencemarketresearch.com/market-research/recombinant-cell-culture-supplements-market.asp

Press Release Source: https://www.persistencemarketresearch.com/mediarelease/recombinant-cell-culture-supplements-market.asp

Continued here:
Recombinant Cell Culture Supplements Receive a Boost from Stem Cell Research Ventures; Demand for Novel Vaccines to Act as a Growth Lever, Says PMR -...